Advertisement

Gastric Cancer

, Volume 6, Supplement 1, pp 13–18 | Cite as

Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer

  • Takuji Mori
  • Yoshiyuki Fujiwara
  • Masahiko Yano
  • Shigeyuki Tamura
  • Takushi Yasuda
  • Shuji Takiguchi
  • Morito Monden
Article

Abstract

Background

Favorable results have been reported for the novel oral anticancer agent S-1 (TS-1®) in clinical studies of advanced gastric cancer with peritoneal dissemination. In the present study we assessed its pharmacokinetics, inhibitory effects, and effect on survival time in an animal model.

Methods

A model of peritoneal dissemination was created by intraperitoneally implanting 4-week-old female BALBc nu/nu mice with the human gastric cancer cell line MKN-45 after transfection with a fluorescent protein-expressing vector. Pharmacokinetics were investigated by measuring intratumor, peritoneal lining, and blood concentrations after the administration of S-1 and fluorouracil (5-FU). The effect of S-1 on survival time was also assessed, by administration once daily to seven animals per group, starting on day 7 after implantation, and survival time was compared with that of an untreated control group. The inhibitory effect of S-1 on peritoneal dissemination was evaluated by killing mice at the start of administration, and 1 and 3 weeks after the start of administration, and examining them for the presence of peritoneal dissemination under a fluorescence stereomicroscope.

Results

Maintenance of high 5-FU concentrations in the intraperitoneal tumors was confirmed in the S-1 group, and survival time was prolonged without any decrease in oral food intake or body weight.

Conclusion

Assessment in a model of peritoneal dissemination of gastric cancer showed that the novel oral anticancer agent S-1 was effective against peritoneal dissemination, and that it improved the survival rate.

Key words

Gastric cancer Peritoneal dissemination S-1 

References

  1. 1.
    Dupont, JB, Lee, JR, Burton, GR, Cohn, I,Jr 1978Adenocarcinoma of the stomach: review of 1497 casesCancer419417PubMedGoogle Scholar
  2. 2.
    Yamada, E, Miyaishi, S, Nakazato, H, Kato, K, Kito, T, Takagi, H,  et al. 1980The surgical treatment of cancer of the stomachInt Surg6538799PubMedGoogle Scholar
  3. 3.
    Fujimura, T, Yonemura, Y, Nakagawara, H, Kitagawa, H, Fushida, S, Nishimura, G,  et al. 2000Subtotal peritonectomy with chemohyperthermic peritoneal perfusion for peritonitis carcinomatosa in gastrointestinal cancerOncol Rep780914PubMedGoogle Scholar
  4. 4.
    Yonemura, Y, Fujimura, T, Fushida, S, Fujita, H, Bando, E, Nishimura, G,  et al. 1999A new surgical approach (peritonectomy) for the treatment of peritoneal disseminationHepatogastroenterology466019PubMedGoogle Scholar
  5. 5.
    Yonemura, Y, Fujimura, T, Fushida, S, Takegawa, S, Kamata, T, Katayama, K,  et al. 1991Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal disseminationWorld J Surg155306PubMedCrossRefGoogle Scholar
  6. 6.
    Yu, W, Whang, I, Suh, I, Averbach, A, Chang, D, Sugarbaker, PH 1998Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancerAnn Surg22834754PubMedCrossRefGoogle Scholar
  7. 7.
    Fujimura, T, Yonemura, Y, Fushida, S, Urade, M, Takegawa, S, Kamata, T,  et al. 1990Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operationCancer656571PubMedGoogle Scholar
  8. 8.
    Shimada, K, Ajani, JA 1999Adjuvant therapy for gastric carcinoma patients in the past 15 years: a review of western and oriental trialsCancer86165768PubMedGoogle Scholar
  9. 9.
    Shirasaka, T, Shimamoto, Y, Ohshimo, H, Yamaguchi, M, Kato, T, Yonekura, K, Fukushima, M 1996Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potential of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulatorsAnticancer Drugs754857PubMedGoogle Scholar
  10. 10.
    Iwazawa, T, Kinuta, M, Yano, H, Matsui, S, Tamagaki, S, Yasue, A,  et al. 2002An oral anticancer drug, TS-1, enabled a patient with advanced gastric cancer with Virchow's metastasis to receive curative resectionGastric Cancer596101PubMedCrossRefGoogle Scholar
  11. 11.
    Iwahashi, M, Nakamori, M, Tani, M, Yamaue, H, Sakaguchi, S, Nakamura, M,  et al. 2001Complete response of highly advanced gastric cancer with peritoneal dissemination after new combined chemotherapy of S-1 and low-dose cisplatin: report of a caseOncology611622PubMedCrossRefGoogle Scholar
  12. 12.
    Kaneko, K, Yano, M, Monden, M 2000Establishment of a visible peritoneal metastatic model from a gastric adenocarcinoma cell line by green fluorescent proteinInt J Oncol168938PubMedGoogle Scholar
  13. 13.
    Fukushima, M 1998Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil, on human tumor xenograftsInt J Oncol136938PubMedGoogle Scholar
  14. 14.
    Unemi, N, Takeda, S, Tajima, K, Kawaguchi, Y, Yasuda, A 1981Effect of coadministration of uracil on the antitumor activity of 1-(Terahydro-2-furanyl)-5-fluorouracil and the level of 5-fluorouracil in AH 130 bearing RatsChemotherapy2916475Google Scholar
  15. 15.
    Matsushima, E, Yoshida, K, Kitamura, R, Yoshida, K 1997Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometryJ Chromatogr B69195104Google Scholar
  16. 16.
    Takechi, T, Nakano, K, Uchida, J, Mita, A, Toko, K, Takeda, S,  et al. 1997Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in ratsCancer Chemother Pharmacol3920511PubMedGoogle Scholar
  17. 17.
    Tatsumi, K, Fukushima, M, Shirasaka, T, Fujii, S 1987Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extractsJpn J Cancer Res7874855PubMedGoogle Scholar
  18. 18.
    Shirasaka, T, Shimamoto, Y, Fukushima, M 1993Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in ratsCancer Res5340049PubMedGoogle Scholar
  19. 19.
    Koizumi, W, Kurihara, M, Nakano, S, Hasegawa, K 2000Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. The S-1 Cooperative Gastric Cancer Study GroupOncology581917PubMedCrossRefGoogle Scholar

Copyright information

© International and Japanese Gastric Cancer Associations 2003

Authors and Affiliations

  • Takuji Mori
    • 1
  • Yoshiyuki Fujiwara
    • 1
  • Masahiko Yano
    • 1
  • Shigeyuki Tamura
    • 1
  • Takushi Yasuda
    • 1
  • Shuji Takiguchi
    • 1
  • Morito Monden
    • 1
  1. 1.Department of Surgery and Clinical Oncology, Graduate School of MedicineOsaka UniversityOsakaJapan

Personalised recommendations